References
1. Dillon SR, Sprecher C, Hammond A, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol . 2004;5(7):752-760. doi:10.1038/ni1084
2. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6.Biochim Biophys Acta . 2011;1813(5):878-888. doi:10.1016/j.bbamcr.2011.01.034
3. Diveu C, Lak-Hal A-HL, Froger J, et al. Predominant expression of the long isoform of GP130-like (GPL) receptor is required for interleukin-31 signaling. Eur Cytokine Netw . 15(4):291-302. http://www.ncbi.nlm.nih.gov/pubmed/15627637.
4. Dreuw A, Radtke S, Pflanz S, Lippok BE, Heinrich PC, Hermanns HM. Characterization of the signaling capacities of the novel gp130-like cytokine receptor. J Biol Chem . 2004;279(34):36112-36120. doi:10.1074/jbc.M401122200
5. Sonkoly E, Muller A, Lauerma AI, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol . 2006;117(2):411-417. doi:10.1016/j.jaci.2005.10.033
6. Cevikbas F, Wang X, Akiyama T, et al. A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1. J Allergy Clin Immunol . 2014;133(2):448-460. doi:10.1016/j.jaci.2013.10.048
7. Gibbs BF, Patsinakidis N, Raap U. Role of the Pruritic Cytokine IL-31 in Autoimmune Skin Diseases. Front Immunol . 2019;10:1383. doi:10.3389/fimmu.2019.01383
8. Roosterman D, Goerge T, Schneider SW, Bunnett NW, Steinhoff M. Neuronal control of skin function: the skin as a neuroimmunoendocrine organ. Physiol Rev . 2006;86(4):1309-1379. doi:10.1152/physrev.00026.2005
9. Maier E, Werner D, Duschl A, Bohle B, Horejs-Hoeck J. Human Th2 but not Th9 cells release IL-31 in a STAT6/NF-κB-dependent way. J Immunol . 2014;193(2):645-654. doi:10.4049/jimmunol.1301836
10. Bilsborough J, Leung DYM, Maurer M, et al. IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. J Allergy Clin Immunol . 2006;117(2):418-425. doi:10.1016/j.jaci.2005.10.046
11. Stott B, Lavender P, Lehmann S, Pennino D, Durham S, Schmidt-Weber CB. Human IL-31 is induced by IL-4 and promotes TH2-driven inflammation.J Allergy Clin Immunol . 2013;132(2):446-54.e5. doi:10.1016/j.jaci.2013.03.050
12. Park K, Park J-H, Yang W-J, Lee J-J, Song M-J, Kim H-P. Transcriptional activation of the IL31 gene by NFAT and STAT6. J Leukoc Biol . 2012;91(2):245-257. doi:10.1189/jlb.0111020
13. Hwang JS, Kim G-C, Park E, et al. NFAT1 and JunB cooperatively regulate IL-31 gene expression in CD4+ T cells in health and disease.J Immunol . 2015;194(4):1963-1974. doi:10.4049/jimmunol.1401862
14. Maier E, Mittermeir M, Ess S, et al. Prerequisites for Functional Interleukin 31 Signaling and Its Feedback Regulation by Suppressor of Cytokine Signaling 3 (SOCS3). J Biol Chem . 2015;290(41):24747-24759. doi:10.1074/jbc.M115.661306
15. Paus R, Schmelz M, Bíró T, Steinhoff M. Frontiers in pruritus research: scratching the brain for more effective itch therapy. J Clin Invest . 2006;116(5):1174-1186. doi:10.1172/JCI28553
16. Cevikbas F, Lerner EA. Physiology and Pathophysiology of Itch.Physiol Rev . 2020;100(3):945-982. doi:10.1152/physrev.00017.2019
17. Steinhoff M, Schmelz M, Szabó IL, Oaklander AL. Clinical presentation, management, and pathophysiology of neuropathic itch.Lancet Neurol . 2018;17(8):709-720. doi:10.1016/S1474-4422(18)30217-5
18. Steinhoff M, Bienenstock J, Schmelz M, Maurer M, Wei E, Bíró T. Neurophysiological, neuroimmunological, and neuroendocrine basis of pruritus. J Invest Dermatol . 2006;126(8):1705-1718. doi:10.1038/sj.jid.5700231
19. Steinhoff M, Cevikbas F, Yeh I, Chong K, Buddenkotte J, Ikoma A. Evaluation and management of a patient with chronic pruritus. J Allergy Clin Immunol . 2012;130(4):1015-6.e7. doi:10.1016/j.jaci.2012.08.006
20. Yosipovitch G, Bernhard JD. Clinical practice. Chronic pruritus.N Engl J Med . 2013;368(17):1625-1634. doi:10.1056/NEJMcp1208814
21. Steinhoff MS, von Mentzer B, Geppetti P, Pothoulakis C, Bunnett NW. Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease. Physiol Rev . 2014;94(1):265-301. doi:10.1152/physrev.00031.2013
22. Ständer S, Steinhoff M, Schmelz M, Weisshaar E, Metze D, Luger T. Neurophysiology of pruritus: cutaneous elicitation of itch. Arch Dermatol . 2003;139(11):1463-1470. doi:10.1001/archderm.139.11.1463
23. Meng J, Moriyama M, Feld M, et al. New mechanism underlying IL-31-induced atopic dermatitis. J Allergy Clin Immunol . 2018;141(5):1677-1689.e8. doi:10.1016/j.jaci.2017.12.1002
24. Meng J, Wang J, Buddenkotte J, Buhl T, Steinhoff M. Role of SNAREs in Atopic Dermatitis-Related Cytokine Secretion and Skin-Nerve Communication. J Invest Dermatol . 2019;139(11):2324-2333. doi:10.1016/j.jid.2019.04.017
25. Bautista DM, Wilson SR, Hoon MA. Why we scratch an itch: the molecules, cells and circuits of itch. Nat Neurosci . 2014;17(2):175-182. doi:10.1038/nn.3619
26. Hoon MA. Molecular dissection of itch. Curr Opin Neurobiol . 2015;34:61-66. doi:10.1016/j.conb.2015.01.017
27. Usoskin D, Furlan A, Islam S, et al. Unbiased classification of sensory neuron types by large-scale single-cell RNA sequencing.Nat Neurosci . 2015;18(1):145-153. doi:10.1038/nn.3881
28. Oh M-H, Oh SY, Lu J, et al. TRPA1-dependent pruritus in IL-13-induced chronic atopic dermatitis. J Immunol . 2013;191(11):5371-5382. doi:10.4049/jimmunol.1300300
29. Imamachi N, Park GH, Lee H, et al. TRPV1-expressing primary afferents generate behavioral responses to pruritogens via multiple mechanisms. Proc Natl Acad Sci U S A . 2009;106(27):11330-11335. doi:10.1073/pnas.0905605106
30. Kido-Nakahara M, Buddenkotte J, Kempkes C, et al. Neural peptidase endothelin-converting enzyme 1 regulates endothelin 1-induced pruritus.J Clin Invest . 2014;124(6):2683-2695. doi:10.1172/JCI67323
31. Wilson SR, Thé L, Batia LM, et al. The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch.Cell . 2013;155(2):285-295. doi:10.1016/j.cell.2013.08.057
32. Oetjen LK, Mack MR, Feng J, et al. Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch. Cell . 2017;171(1):217-228.e13. doi:10.1016/j.cell.2017.08.006
33. Campion M, Smith L, Gatault S, Métais C, Buddenkotte J, Steinhoff M. Interleukin-4 and interleukin-13 evoke scratching behaviour in mice.Exp Dermatol . 2019;28(12):1501-1504. doi:10.1111/exd.14034
34. Werfel T, Allam J-P, Biedermann T, et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol . 2016;138(2):336-349. doi:10.1016/j.jaci.2016.06.010
35. Cevikbas F, Braz JM, Wang X, et al. Synergistic antipruritic effects of gamma aminobutyric acid A and B agonists in a mouse model of atopic dermatitis. J Allergy Clin Immunol . 2017;140(2):454-464.e2. doi:10.1016/j.jaci.2017.02.001
36. Kato A, Fujii E, Watanabe T, et al. Distribution of IL-31 and its receptor expressing cells in skin of atopic dermatitis. J Dermatol Sci . 2014;74(3):229-235. doi:10.1016/j.jdermsci.2014.02.009
37. Feld M, Garcia R, Buddenkotte J, et al. The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves. J Allergy Clin Immunol . 2016;138(2):500-508.e24. doi:10.1016/j.jaci.2016.02.020
38. Tobin D, Nabarro G, Baart de la Faille H, van Vloten WA, van der Putte SC, Schuurman HJ. Increased number of immunoreactive nerve fibers in atopic dermatitis. J Allergy Clin Immunol . 1992;90(4 Pt 1):613-622. doi:10.1016/0091-6749(92)90134-n
39. Cevikbas F, Steinhoff A, Homey B, Steinhoff M. Neuroimmune interactions in allergic skin diseases. Curr Opin Allergy Clin Immunol . 2007;7(5):365-373. doi:10.1097/ACI.0b013e3282a644d2
40. Lerner EA. Is the Nervous System More Important Than the Immune System in Itch and Atopic Dermatitis? J Investig dermatology Symp Proc . 2018;19(2):S94. doi:10.1016/j.jisp.2018.10.002
41. Tominaga M, Takamori K. Itch and nerve fibers with special reference to atopic dermatitis: therapeutic implications. J Dermatol . 2014;41(3):205-212. doi:10.1111/1346-8138.12317
42. Emtestam L, Hagströmer L, Dou Y-C, Sartorius K, Johansson O. PGP 9.5 distribution patterns in biopsies from early lesions of atopic dermatitis. Arch Dermatol Res . 2012;304(10):781-785. doi:10.1007/s00403-012-1246-0
43. Hosokawa T, Kusugami K, Ina K, et al. Interleukin-6 and soluble interleukin-6 receptor in the colonic mucosa of inflammatory bowel disease. J Gastroenterol Hepatol . 1999;14(10):987-996. doi:10.1046/j.1440-1746.1999.01989.x
44. Xing Z, Gauldie J, Cox G, et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest . 1998;101(2):311-320. doi:10.1172/JCI1368
45. Robinson ES, Werth VP. The role of cytokines in the pathogenesis of cutaneous lupus erythematosus. Cytokine . 2015;73(2):326-334. doi:10.1016/j.cyto.2015.01.031
46. West NR, Hegazy AN, Owens BMJ, et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med . 2017;23(5):579-589. doi:10.1038/nm.4307
47. Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol . 2018;18(12):773-789. doi:10.1038/s41577-018-0066-7
48. Imai Y. Interleukin-33 in atopic dermatitis. J Dermatol Sci . 2019;96(1):2-7. doi:10.1016/j.jdermsci.2019.08.006
49. Lee J-H, Wang L-C, Yu H-H, Lin Y-T, Yang Y-H, Chiang B-L. Type I IL-1 receptor (IL-1RI) as potential new therapeutic target for bronchial asthma. Mediators Inflamm . 2010;2010:567351. doi:10.1155/2010/567351
50. Hawro T, Saluja R, Weller K, Altrichter S, Metz M, Maurer M. Interleukin-31 does not induce immediate itch in atopic dermatitis patients and healthy controls after skin challenge. Allergy . 2014;69(1):113-117. doi:10.1111/all.12316
51. Vocca L, Di Sano C, Uasuf CG, et al. IL-33/ST2 axis controls Th2/IL-31 and Th17 immune response in allergic airway diseases.Immunobiology . 2015;220(8):954-963. doi:10.1016/j.imbio.2015.02.005
52. Singh B, Jegga AG, Shanmukhappa KS, et al. IL-31-Driven Skin Remodeling Involves Epidermal Cell Proliferation and Thickening That Lead to Impaired Skin-Barrier Function. PLoS One . 2016;11(8):e0161877. doi:10.1371/journal.pone.0161877
53. Cornelissen C, Marquardt Y, Czaja K, et al. IL-31 regulates differentiation and filaggrin expression in human organotypic skin models. J Allergy Clin Immunol . 2012;129(2):426-433, 433.e1-8. doi:10.1016/j.jaci.2011.10.042
54. Hänel KH, Pfaff CM, Cornelissen C, et al. Control of the Physical and Antimicrobial Skin Barrier by an IL-31-IL-1 Signaling Network.J Immunol . 2016;196(8):3233-3244. doi:10.4049/jimmunol.1402943
55. Santamaria LF, Perez Soler MT, Hauser C, Blaser K. Allergen specificity and endothelial transmigration of T cells in allergic contact dermatitis and atopic dermatitis are associated with the cutaneous lymphocyte antigen. Int Arch Allergy Immunol . 107(1-3):359-362. doi:10.1159/000237032
56. Kasraie S, Niebuhr M, Baumert K, Werfel T. Functional effects of interleukin 31 in human primary keratinocytes. Allergy . 2011;66(7):845-852. doi:10.1111/j.1398-9995.2011.02545.x
57. Santamaria Babi LF, Picker LJ, Perez Soler MT, et al. Circulating allergen-reactive T cells from patients with atopic dermatitis and allergic contact dermatitis express the skin-selective homing receptor, the cutaneous lymphocyte-associated antigen. J Exp Med . 1995;181(5):1935-1940. doi:10.1084/jem.181.5.1935
58. Akdis M, Akdis CA, Weigl L, Disch R, Blaser K. Skin-homing, CLA+ memory T cells are activated in atopic dermatitis and regulate IgE by an IL-13-dominated cytokine pattern: IgG4 counter-regulation by CLA- memory T cells. J Immunol . 1997;159(9):4611-4619. http://www.ncbi.nlm.nih.gov/pubmed/9379063.
59. Khattri S, Shemer A, Rozenblit M, et al. Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. J Allergy Clin Immunol . 2014;133(6):1626-1634. doi:10.1016/j.jaci.2014.03.003
60. Lin Y-T, Wang C-T, Chiang B-L. Role of bacterial pathogens in atopic dermatitis. Clin Rev Allergy Immunol . 2007;33(3):167-177. doi:10.1007/s12016-007-0044-5
61. Torres MJ, Gonzalez FJ, Corzo JL, et al. Circulating CLA+ lymphocytes from children with atopic dermatitis contain an increased percentage of cells bearing staphylococcal-related T-cell receptor variable segments. Clin Exp Allergy . 1998;28(10):1264-1272. doi:10.1046/j.1365-2222.1998.00397.x
62. Szegedi K, van Lier A, Res PC, et al. House dust mite allergens Der f and Der p induce IL-31 production by blood-derived T cells from atopic dermatitis patients. Exp Dermatol . 2018;27(4):393-395. doi:10.1111/exd.13438
63. Horejs-Hoeck J, Schwarz H, Lamprecht S, et al. Dendritic cells activated by IFN-γ/STAT1 express IL-31 receptor and release proinflammatory mediators upon IL-31 treatment. J Immunol . 2012;188(11):5319-5326. doi:10.4049/jimmunol.1101044
64. Wong C-K, Leung KM-L, Qiu H-N, Chow JY-S, Choi AOK, Lam CW-K. Activation of eosinophils interacting with dermal fibroblasts by pruritogenic cytokine IL-31 and alarmin IL-33: implications in atopic dermatitis. PLoS One . 2012;7(1):e29815. doi:10.1371/journal.pone.0029815
65. Cheung PF-Y, Wong C-K, Ho AW-Y, Hu S, Chen D-P, Lam CW-K. Activation of human eosinophils and epidermal keratinocytes by Th2 cytokine IL-31: implication for the immunopathogenesis of atopic dermatitis. Int Immunol . 2010;22(6):453-467. doi:10.1093/intimm/dxq027
66. Moyle M, Cevikbas F, Harden JL, Guttman-Yassky E. Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches. Exp Dermatol . 2019;28(7):756-768. doi:10.1111/exd.13911
67. Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med . 2014;371(2):130-139. doi:10.1056/NEJMoa1314768
68. Grimstad O, Sawanobori Y, Vestergaard C, et al. Anti-interleukin-31-antibodies ameliorate scratching behaviour in NC/Nga mice: a model of atopic dermatitis. Exp Dermatol . 2009;18(1):35-43. doi:10.1111/j.1600-0625.2008.00766.x
69. Arai I, Tsuji M, Miyagawa K, Takeda H, Akiyama N, Saito S. Repeated administration of IL-31 upregulates IL-31 receptor A (IL-31RA) in dorsal root ganglia and causes severe itch-associated scratching behaviour in mice. Exp Dermatol . 2015;24(1):75-78. doi:10.1111/exd.12587
70. Kasutani K, Fujii E, Ohyama S, et al. Anti-IL-31 receptor antibody is shown to be a potential therapeutic option for treating itch and dermatitis in mice. Br J Pharmacol . 2014;171(22):5049-5058. doi:10.1111/bph.12823
71. Kabashima K, Furue M, Hanifin JM, et al. Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study. J Allergy Clin Immunol . 2018;142(4):1121-1130.e7. doi:10.1016/j.jaci.2018.03.018
72. Nemoto O, Furue M, Nakagawa H, et al. The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-co. Br J Dermatol . 2016;174(2):296-304. doi:10.1111/bjd.14207
73. Ruzicka T, Hanifin JM, Furue M, et al. Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis. N Engl J Med . 2017;376(9):826-835. doi:10.1056/NEJMoa1606490
74. Kabashima K, Matsumura T, Komazaki H, Kawashima M, Nemolizumab-JP01 Study Group. Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus. N Engl J Med . 2020;383(2):141-150. doi:10.1056/NEJMoa1917006
75. Oyama S, Kitamura H, Kuramochi T, et al. Cynomolgus monkey model of interleukin-31-induced scratching depicts blockade of human interleukin-31 receptor A by a humanized monoclonal antibody. Exp Dermatol . 2018;27(1):14-21. doi:10.1111/exd.13236
76. Gonzales AJ, Humphrey WR, Messamore JE, et al. Interleukin-31: its role in canine pruritus and naturally occurring canine atopic dermatitis. Vet Dermatol . 2013;24(1):48-53.e11-2. doi:10.1111/j.1365-3164.2012.01098.x
77. Michels GM, Ramsey DS, Walsh KF, et al. A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis. Vet Dermatol . 2016;27(6):478-e129. doi:10.1111/vde.12376
78. Michels GM, Walsh KF, Kryda KA, et al. A blinded, randomized, placebo-controlled trial of the safety of lokivetmab (ZTS-00103289), a caninized anti-canine IL-31 monoclonal antibody in client-owned dogs with atopic dermatitis. Vet Dermatol . 2016;27(6):505-e136. doi:10.1111/vde.12364
79. Lewis KE, Holdren MS, Maurer MF, et al. Interleukin (IL) 31 induces in cynomolgus monkeys a rapid and intense itch response that can be inhibited by an IL-31 neutralizing antibody. J Eur Acad Dermatol Venereol . 2017;31(1):142-150. doi:10.1111/jdv.13794
80. Silverberg JI, Pinter A, Pulka G, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol . 2020;145(1):173-182. doi:10.1016/j.jaci.2019.08.013
81. Chattopadhyay S, Tracy E, Liang P, Robledo O, Rose-John S, Baumann H. Interleukin-31 and oncostatin-M mediate distinct signaling reactions and response patterns in lung epithelial cells. J Biol Chem . 2007;282(5):3014-3026. doi:10.1074/jbc.M609655200
82. Ouyang H, Cheng J, Zheng Y, Du J. Role of IL-31 in regulation of Th2 cytokine levels in patients with nasal polyps. Eur Arch Otorhinolaryngol . 2014;271(10):2703-2709. doi:10.1007/s00405-014-2913-x
83. Perrigoue JG, Zaph C, Guild K, Du Y, Artis D. IL-31-IL-31R interactions limit the magnitude of Th2 cytokine-dependent immunity and inflammation following intestinal helminth infection. J Immunol . 2009;182(10):6088-6094. doi:10.4049/jimmunol.0802459
84. Fukada T, Hibi M, Yamanaka Y, et al. Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. Immunity . 1996;5(5):449-460. doi:10.1016/s1074-7613(00)80501-4
85. Fukada T, Ohtani T, Yoshida Y, et al. STAT3 orchestrates contradictory signals in cytokine-induced G1 to S cell-cycle transition.EMBO J . 1998;17(22):6670-6677. doi:10.1093/emboj/17.22.6670
86. Lei Z, Liu G, Huang Q, et al. SCF and IL-31 rather than IL-17 and BAFF are potential indicators in patients with allergic asthma.Allergy . 2008;63(3):327-332. doi:10.1111/j.1398-9995.2007.01566.x
87. Guarneri F, Minciullo PL, Mannucci C, et al. IL-31 and IL-33 circulating levels in allergic contact dermatitis. Eur Ann Allergy Clin Immunol . 2015;47(5):156-158. http://www.ncbi.nlm.nih.gov/pubmed/26357000.
88. Endo Y, Hirahara K, Iinuma T, et al. The interleukin-33-p38 kinase axis confers memory T helper 2 cell pathogenicity in the airway.Immunity . 2015;42(2):294-308. doi:10.1016/j.immuni.2015.01.016
89. Ip WK, Wong CK, Li MLY, Li PW, Cheung PFY, Lam CWK. Interleukin-31 induces cytokine and chemokine production from human bronchial epithelial cells through activation of mitogen-activated protein kinase signalling pathways: implications for the allergic response.Immunology . 2007;122(4):532-541. doi:10.1111/j.1365-2567.2007.02668.x
90. Perrigoue JG, Li J, Zaph C, et al. IL-31-IL-31R interactions negatively regulate type 2 inflammation in the lung. J Exp Med . 2007;204(3):481-487. doi:10.1084/jem.20061791
91. Shah SA, Ishinaga H, Hou B, Okano M, Takeuchi K. Effects of interleukin-31 on MUC5AC gene expression in nasal allergic inflammation.Pharmacology . 2013;91(3-4):158-164. doi:10.1159/000346609
92. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet (London, England) . 2007;369(9573):1641-1657. doi:10.1016/S0140-6736(07)60751-X
93. Koenecke C, Förster R. CCR9 and inflammatory bowel disease.Expert Opin Ther Targets . 2009;13(3):297-306. doi:10.1517/14728220902762928
94. Dambacher J, Beigel F, Seiderer J, et al. Interleukin 31 mediates MAP kinase and STAT1/3 activation in intestinal epithelial cells and its expression is upregulated in inflammatory bowel disease. Gut . 2007;56(9):1257-1265. doi:10.1136/gut.2006.118679
95. Yagi Y, Andoh A, Nishida A, et al. Interleukin-31 stimulates production of inflammatory mediators from human colonic subepithelial myofibroblasts. Int J Mol Med . 2007;19(6):941-946. http://www.ncbi.nlm.nih.gov/pubmed/17487427.
96. Ständer S, Yosipovitch G, Legat FJ, et al. Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis. N Engl J Med . 2020;382(8):706-716. doi:10.1056/NEJMoa1908316
97. Broxmeyer HE, Li J, Hangoc G, et al. Regulation of myeloid progenitor cell proliferation/survival by IL-31 receptor and IL-31.Exp Hematol . 2007;35(4 Suppl 1):78-86. doi:10.1016/j.exphem.2007.01.028
Table 1: Clinical trial design for completed trials testing nemolizumab efficacy in AD and PN